###begin article-title 0
###xml 19 24 19 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
GATA3 protein as a MUC1 transcriptional regulator in breast cancer cells
###end article-title 0
###begin p 1
This is an open access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Introduction
###end title 2
###begin p 3
###xml 183 187 183 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC2</italic>
###xml 189 194 189 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC3 </italic>
###xml 198 202 198 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC4</italic>
###xml 493 499 493 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA3 </italic>
###xml 503 508 503 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 607 612 607 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
Recent studies have demonstrated that members of the GATA-binding protein (GATA) family (GATA4 and GATA5) might have pivotal roles in the transcriptional upregulation of mucin genes (MUC2, MUC3 and MUC4) in gastrointestinal epithelium. The zinc-finger GATA3 transcription factor has been reported to be involved in the growth control and differentiation of breast epithelial cells. In SAGE (serial analysis of gene expression) studies we observed an intriguing significant correlation between GATA3 and MUC1 mRNA expression in breast carcinomas. We therefore designed the present study to elucidate whether MUC1 expression is regulated by GATA3 in breast cancer cells.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 34 39 34 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 64 68 64 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis </italic>
###xml 302 308 302 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA3 </italic>
###xml 312 317 312 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 341 350 341 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 407 413 407 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA3 </italic>
###xml 417 422 417 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
Promoter sequence analysis of the MUC1 gene identified six GATA cis consensus elements in the 5' flanking region (GATA1, GATA3 and four GATA-like sequences). Chromatin immunoprecipitation and electrophoretic mobility-shift assays were employed to study the presence of a functional GATA3-binding site. GATA3 and MUC1 expression was analyzed in vitro with a GATA3 knockdown assay. Furthermore, expression of GATA3 and MUC1 genes was analyzed by real-time RT-PCR and immunohistochemistry on breast cancer-specific tissue microarrays.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 68 73 68 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 310 316 310 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA3 </italic>
###xml 320 325 320 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 421 423 421 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 533 535 533 535 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 562 564 562 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
We confirmed the presence of a functional GATA3-binding site on the MUC1 promoter region in the MCF7 cell line. We determined that GATA3 knockdown assays led to a decrease in MUC1 protein expression in MCF7 and T47D cells. In addition, we detected a statistically significant correlation in expression between GATA3 and MUC1 genes at the mRNA and protein levels both in normal breast epithelium and in breast carcinomas (p = 0.01). GATA3 expression was also highly associated with estrogen receptor and progesterone receptor status (p = 0.0001) and tumor grade (p = 0.004) in breast carcinomas.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 113 118 113 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
Our study provides evidence indicating that GATA3 is probably a mediator for the transcriptional upregulation of MUC1 expression in some breast cancers.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 246 247 246 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 378 383 378 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA1</italic>
###xml 385 390 385 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA2</italic>
###xml 396 402 396 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA3 </italic>
###xml 466 471 466 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA4</italic>
###xml 473 478 473 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA5</italic>
###xml 484 490 484 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA6 </italic>
###xml 622 623 622 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
GATA3 (GATA-binding protein 3) belongs to a family of transcription factors (GATA1 to GATA6) that bind with high affinity to the consensus sequence (A/T)GATA(A/G) and share a steroid-hormone-receptor superfamily C4 zinc-finger DNA-binding motif [1]. GATA factors are classified into two subfamilies on the basis of structural features and expression patterns. The expression of GATA1, GATA2, and GATA3 has been detected predominantly in hematopoietic cells, whereas GATA4, GATA5, and GATA6 are expressed mainly in the cardiovascular system and in endodermal-derived tissues including liver, lung, pancreas, and intestine [2]. The function of GATA factors is modulated by their interaction with other transcription factors, transcriptional coactivators and co-repressors.
###end p 11
###begin p 12
###xml 97 103 97 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA3 </italic>
###xml 192 193 184 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 236 237 228 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 238 239 230 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 389 391 381 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 425 431 417 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA3 </italic>
###xml 636 642 628 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA3 </italic>
###xml 643 645 635 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 897 899 889 891 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1028 1032 1020 1024 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC2</italic>
###xml 1034 1038 1026 1030 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC3</italic>
###xml 1044 1048 1036 1040 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC4</italic>
###xml 1076 1081 1068 1073 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TFF1 </italic>
###xml 1085 1089 1077 1081 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TFF2</italic>
###xml 1182 1184 1174 1176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1185 1187 1177 1179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 379 387 <span type="species:ncbi:9606">patients</span>
In genome-wide expression profile studies from our laboratory we observed that the expression of GATA3 is highly correlated with estrogen receptor-alpha (ERalpha) status in breast carcinomas [3] similar results were reported by others [4-9]. Parikh and colleagues (2005) suggested that GATA3 expression might be associated with responsiveness to hormone therapy in breast cancer patients [10]. Furthermore, the expression of GATA3 has been shown to correlate with specific breast cancer phenotypes, defined as luminal type A, carrying an improved disease-free survival and overall survival when compared with tumors that do not express GATA3 [11]. It has been reported that GATA3 may be involved in growth control and differentiation in breast epithelial cells mediating the transcriptional activation of several genes such as those encoding cytokeratins 5, 6 and 17, and trefoil factors 1 and 3 [12]. Recent evidence indicates that the proteins GATA4, GATA5, and GATA6 may be important in the upregulation of mucin expression (MUC2, MUC3, and MUC4) and trefoil factor genes (TFF1 and TFF2), events that are in turn associated with gastrointestinal epithelial cell differentiation [13-15].
###end p 12
###begin p 13
###xml 182 184 182 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 206 211 206 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 302 307 302 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 387 389 387 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 440 445 440 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 508 510 508 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
The MUC1 glycoprotein is a member of the mucin family of proteins, expressed mostly on the apical membrane of various glandular epithelia such as in luminal breast epithelial cells [16]. The association of MUC1 overexpression with loss of cell polarity has been observed in breast carcinomas. Abnormal MUC1 expression leads to a loss of cell-cell and cell-extracellular-matrix adhesion [17]. It was further determined that this increase in MUC1 expression is due mainly to transcriptional regulatory events [18].
###end p 13
###begin p 14
###xml 38 43 38 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 73 75 73 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 76 78 76 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 320 325 316 321 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 326 328 322 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 329 331 325 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 332 334 328 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 370 375 366 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 455 460 451 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 32 37 <span type="species:ncbi:9606">human</span>
The 5'-regulatory region of the human MUC1 gene was analyzed previously [19-21]. Several consensus binding sites for transcription factors were observed in this promoter region, such as those for the SP1, STAT1, STAT3, NF-kappaB, MZF1 and DbpA proteins, all of which may be involved in the transcriptional regulation of MUC1 [18,20,22]. However, the factors determining MUC1 tissue-specific expression remain largely unknown, as do the mechanisms causing MUC1 overexpression in tumors.
###end p 14
###begin p 15
###xml 93 99 93 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA3 </italic>
###xml 103 108 103 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 250 255 250 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 370 375 370 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
Global gene expression studies pointed to a significant correlation in the overexpression of GATA3 and MUC1 genes commonly observed in breast cancer. Interestingly, we also observed the presence of multiple putative GATA-binding sites throughout the MUC1 promoter. Thus, the aim of this study was to evaluate the role of GATA3 as a putative transcriptional regulator of MUC1 in breast cancer.
###end p 15
###begin title 16
Materials and methods
###end title 16
###begin title 17
Serial analysis of gene expression database mining
###end title 17
###begin p 18
###xml 211 219 211 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
###xml 629 631 629 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 684 690 684 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA1 </italic>
###xml 704 710 704 710 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA2 </italic>
###xml 724 730 724 730 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA3 </italic>
###xml 744 750 744 750 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA4 </italic>
###xml 764 770 764 770 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA5 </italic>
###xml 784 790 784 790 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA6 </italic>
###xml 804 809 804 809 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 827 832 827 832 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 933 935 933 935 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1310 1312 1310 1312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
To perform a comparative analysis of the GATA family members expressed in breast tissue, we analyzed 47 breast SAGE (serial analysis of gene expression) libraries: 4 normal breast epithelium, 8 ductal carcinoma in situ (DCIS), 33 invasive ductal carcinomas (IDCs), and the MCF7 and ZR75 breast cancer cell lines. To this end, we combined 29 breast cancer SAGE libraries generated by us at a resolution of 100,000 tags per library (Aldaz Laboratory) with 18 SAGE libraries (generated at the Polyak Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA) downloaded from the Cancer Genome Anatomy Project - SAGE Genie database [23]. SAGE data management and tag-to-gene matching for GATA1 (GCCTCCAGAG), GATA2 (GACAGTTGTT), GATA3 (AAGGATGCCA), GATA4 (TCTCTCCCCT), GATA5 (TCCTGGCATA), GATA6 (GAGAAGATCA), ESR1 (AGCAGGTGCC), and MUC1 (CCTGGGAAGT) were performed with a suite of web-based SAGE library annotation tools developed by us [24]. To enable the visualization and illustration of our analyses, we used the TIGR MultiExperiment Viewer (MeV 2.2) software (The Institute for Genomic Research, Rockville, MD, USA). This tool was employed for normalization and average clustering of the SAGE data. Spearman's test was employed for a correlation analysis of transcripts. The CGAP-dbEST and Oncomine databases [25] were employed for collection and visualization of gene expression profiles of the previously mentioned transcripts from publicly available breast cancer ESTs and microarray data sets (Additional file 1).
###end p 18
###begin title 19
Real-time RT-PCR expression analysis in breast carcinomas
###end title 19
###begin p 20
###xml 350 356 333 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA3 </italic>
###xml 360 365 343 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 598 602 572 574 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 802 804 772 774 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
For validation studies, total RNA was isolated from an independent set of 36 snap-frozen breast carcinomas (stages I and II: 13 ERalpha-negative tumors and 23 ERalpha-positive tumors) using TRIzol reagent (Invitrogen, San Francisco, CA, USA). Template cDNAs were synthesized with the SuperScripttrade mark First-strand Synthesis System (Invitrogen). GATA3 and MUC1 primers and probes were obtained from Applied Biosystems (TaqMan Assays-on-Demandtrade mark Gene Expression Products; Foster City, CA, USA). All the PCR reactions were performed with the TaqMan PCR Core Reagents kit and the ABI Prism(R) 7700 Sequence Detection System (Applied Biosystems). Experiments were performed in duplicate for each data point and 18S rRNA was used as control. Results are expressed as means +/- 2 SEM based on log2 transformation of normalized real-time RT-PCR values of the assayed genes.
###end p 20
###begin title 21
Tissue microarray and immunostaining analysis
###end title 21
###begin p 22
###xml 454 455 454 455 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 456 458 456 458 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 1115 1118 1115 1116 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
###xml 1188 1190 1186 1188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 704 708 <span type="species:ncbi:9925">goat</span>
We used breast-specific tissue microarrays (TMAs) from two sources (Fox Chase Cancer Center, Philadelphia, and Cooperative Breast Cancer Tissue Resource, NCI-CBCTR) for GATA3 and MUC1 protein expression profiling. We analyzed a total of 263 cases (38 normal tissues (19 DCIS and 206 IDCs). Information on ER and progesterone receptor (PR) status was available for all IDC cases. Before immunostaining, endogenous peroxidase activity was blocked with 3% H2O2 in water for 10 minutes. Heat-induced epitope retrieve was performed with 1.0 mM EDTA buffer pH 8.0 for 10 minutes in a microwave oven followed by cooling for 20 minutes. To block non-specific antibody binding, the slides were incubated with 10% goat serum in PBS for 30 minutes. Primary monoclonal anti-GATA3 (HG3-31: SC-268; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and anti-MUC1 (VU4H5: SC-7313; Santa Cruz Biotechnology) antibodies were used at 1:50 and 1:100 dilutions respectively. Antibody detection was performed using diaminobenzidine (DAB). Staining intensity was determined by means of a Chromavision Automated Cellular Imaging System (ACIS(R)) with the generic DAB software application, as described previously [26]. This software determines brown intensity regardless of the area covered by the positive cells.
###end p 22
###begin p 23
###xml 188 194 188 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA3 </italic>
###xml 198 203 198 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 558 560 558 560 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 603 607 603 605 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
Multivariate analysis was performed by principal components analysis (PCA). Variables were codified and transformed as follows: negative staining (0) and positive staining (1) for ER, PR, GATA3 and MUC1 expression; normal tissue (0), DCIS (1) and IDC (2) for histology; lymph node-negative (0) and lymph node-positive (1) status; and low (1), moderate (2) and high (3) tumor grade. To enable visualization of the factorial analysis, we employed a three-dimensional representation of component plot in rotated space. The basic significance level was fixed at p < 0.05 and all data were analyzed with SPSS(R) statistical software (SPSS Inc., Chicago, IL, USA).
###end p 23
###begin title 24
Cell culture, western blot and immunocytochemistry analyses
###end title 24
###begin p 25
The estrogen-dependent breast cancer cell lines MCF7 and T47D were grown in RPMI-1640 medium (Gibco, Gaithersburg, MD, USA) supplemented with 10% (v/v) FBS (Bioser, Buenos Aires, Argentina), 10 U/ml penicillin G, and 10 mug/ml streptomycin.
###end p 25
###begin p 26
###xml 69 70 69 70 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 351 354 350 351 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
###xml 429 434 <span type="species:ncbi:10090">mouse</span>
###xml 511 522 <span type="species:ncbi:3704">horseradish</span>
###xml 576 581 <span type="species:ncbi:10090">mouse</span>
Trypan blue staining was used to assess cell viability. Cells (3 x 106) were lysed with 1 ml of RIPA buffer (50 mM Tris pH 7.5, 150 mM NaCl, 0.5% sodium deoxycholate, 1% Triton X-100, 0.1% SDS) containing protease inhibitor. For western blotting, 50 mul of cell extract was separated by 10% SDS-PAGE and transferred to nitrocellulose membrane (Protran(R); BioScience, Dassel, Germany). Immunodetection was performed with a GATA3 mouse monoclonal antibody (HG3-31) at 1:300 dilution, followed by incubation with horseradish peroxidase (HRP)-conjugated secondary antibody (anti-mouse-HRP; Sigma, St Louis, MO, USA) at 1:1000 dilution. Immunostaining was performed with DAB as substrate.
###end p 26
###begin p 27
###xml 263 267 <span type="species:ncbi:9925">goat</span>
###xml 273 278 <span type="species:ncbi:10090">mouse</span>
MCF7 cells were also grown on coverslips; these preparations were washed twice with 1 x PBS and fixed with 10% formaldehyde in 1 x PBS. Immunodetection of GATA3 was assessed with HG3-31 monoclonal antibody. Primary antibodies were detected with biotin-conjugated goat anti-mouse IgG, followed by incubation with streptavidin-conjugated HRP and using DAB as a substrate. The cells grown on coverslips were counterstained with hematoxylin and examined by light microscopy.
###end p 27
###begin title 28
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
MUC1 promoter sequence analysis and chromatin immunoprecipitation
###end title 28
###begin p 29
###xml 35 40 35 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 29 34 <span type="species:ncbi:9606">human</span>
The complete sequence of the human MUC1 promoter region was obtained from GenBank (accession no. ). We used the DNAMAN software (Version 4.15; Lynnon BioSoft, Vaudreuil-Dorion, Quebec, Canada) to identify putative GATA-binding sites (A/T-GATA-A/G) in this regulatory sequence.
###end p 29
###begin p 30
###xml 339 340 339 340 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 666 671 <span type="species:ncbi:10090">mouse</span>
MCF7 breast cancer cells were grown to 90% confluence; culture medium was then removed. Cells were washed and fixed with 1% formaldehyde in 1 x PBS for 10 minutes at room temperature. Fixed cells were washed twice with 1 x PBS, scraped off and incubated in 1 ml of lysis buffer A (20 mM HEPES pH 7.9, 25% glycerol, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 1 mM phenylmethylsulphonyl fluoride), followed by a second incubation in 300 mul of lysis buffer B (50 mM Tris-HCl pH 8.0, 1 mM EDTA, 150 mM NaCl, 1% SDS, 2% Triton X-100). The cell lysate was then sonicated with a Branson Sonifier 450 (30-second pulses at 40% output) and subjected to immunoprecipitation with mouse monoclonal antibody HG3-31 against GATA3, at 4degreesC for 1 hour; 50 mul of Protein A-Sepharose (1:1 slurry) was added to the reaction and incubated at 4degreesC for 4 hours. The unbound proteins were removed by washing the Protein A-Sepharose with Triton buffer (50 mM Tris-HCl pH 8.0, 1 mM EDTA, 150 mM NaCl, 0.1% Triton X-100) and 1 x PBS. The antigen-antibody complex was eluted with SDS-NaCl-dithiothreitol (DTT) buffer (62.5 mM Tris-HCl pH 6.8, 200 mM NaCl, 2% SDS, 10 mM DTT). The eluted protein-DNA complex was incubated overnight at 68degreesC. DNA was isolated with the phenol/chloroform extraction and ethanol precipitation protocol.
###end p 30
###begin p 31
###xml 63 64 63 64 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 99 106 98 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">muc1p1 </italic>
###xml 162 169 161 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">muc1p1 </italic>
###xml 258 265 257 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">muc1p2 </italic>
###xml 321 328 320 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink">muc1p2 </italic>
###xml 424 428 423 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq </italic>
###xml 817 819 787 789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
The PCR reactions were performed with 15 ng of DNA, 2.5 mM MgCl2, each dNTP at 200 muM, 25 pmol of muc1p1 forward primer (5'-tagaagggtggggctattcc-3'), 25 pmol of muc1p1 reverse primer (5'-taggtcgaggtcctgtacag-3', flanking the GATA1-binding site), 25 pmol of muc1p2 forward primer (5'-tttggctgatttggggatgc-3'), 25 pmol of muc1p2 reverse primer (5'-aatattgcactcgtcccgtc-3', flanking the GATA3-binding site), and 1.25 units of Taq DNA polymerase (Promega, Madison, WI, USA), in PCR buffer (20 mM Tris-HCl pH 8.4, 50 mM KCl) in a final volume of 50 mul. The reactions were cycled as follows: 1 cycle of 94degreesC for 2 minutes and 25 cycles of 94degreesC for 1 minute, 56degreesC for 1 minute, and 72degreesC for 1 minute. HLA-DQalpha 1 amplicon (242 bp) was used as control (exon sequence without a GATA-binding site) [27]. Separation and detection of the amplified fragments were performed by electrophoresis on a 6% minigel (19:1 polyacrylamide:bisacrylamide) and staining with silver.
###end p 31
###begin title 32
Electrophoretic mobility-shift assay
###end title 32
###begin p 33
###xml 75 77 75 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 154 159 154 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA </italic>
###xml 242 243 242 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 250 255 250 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 767 768 761 762 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1050 1052 1038 1040 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
Nuclear protein extract from the MCF7 cell line was prepared as described [28]. The following double-stranded DNA probes (27 bp) were used: the wild-type GATA consensus oligonucleotide (5'-cacttgataacagaaagtgataactct-3') as positive control [4]; the MUC1 promoter sequence encoding the putative GATA3-binding site (5'-ggcggatctttgatagactggagtgtc-3'); and a double GATA3-binding site mutated variant (with transitions G-->C and A-->T: 5'-ggcggatctttcttagactggagtgtc-3'). A non-isotopic electrophoretic mobility-shift assay (EMSA) was performed with 5 mug of nuclear cell extracts and 50 ng of the probe, 1 mug of salmon testes DNA (Sigma-Aldrich, St Louis, MO, USA) in a 5 x binding reaction buffer (100 mM Hepes pH 7.9, 250 mM KCl, 2.5 mM DTT, 0.25 mM EDTA, 5 mM MgCl2, 25% glycerol). After 20 minutes the samples were separated on a 10% polyacrylamide (39:1 polyacrylamide:bisacrylamide) at a constant temperature of 4degreesC with 1 x Tris-borate-EDTA (45 mA for 4.5 hours). Gels were stained with a previously described silver staining technique [27]. Similarly, for the supershift assay, 1 mug of specific antibody (anti-GATA3) or control antibody (anti-ERbeta) was incubated for 20 minutes in the MCF7 nuclear protein extract before the addition of probes. Samples were size separated by electrophoresis in a 10% polyacrylamide minigel (39:1 polyacrylamide:bisacrylamide) at room temperature with 0.5 x Tris-borate-EDTA.
###end p 33
###begin title 34
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA3 </italic>
GATA3 anti-sense phosphorothioate oligonucleotide assay
###end title 34
###begin p 35
###xml 97 103 97 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA3 </italic>
###xml 134 136 134 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 143 149 143 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA3 </italic>
###xml 386 390 386 388 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 468 474 465 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA3 </italic>
###xml 1056 1060 <span type="species:ncbi:9925">goat</span>
###xml 1066 1071 <span type="species:ncbi:10090">mouse</span>
###xml 1113 1117 <span type="species:ncbi:9925">goat</span>
###xml 1123 1139 <span type="species:ncbi:10032">Armenian hamster</span>
Anti-sense oligodeoxynucleotides were synthesized that matched the translational start region of GATA3 (5'-cgccgtcacctccatggcctc-3') [29]. The GATA3 anti-sense oligodeoxynucleotide used was synthesized on a phosphorothioate backbone to improve resistance to endonucleases (IDT, Coralville, IA, USA). MCF7 and T47D cells were plated on 50 mm cultured dishes at 50% confluence in Opti-MEM(R) I Reduced Serum Medium (Invitrogen) and transiently transfected with 3 mug of GATA3 anti-sense mixed with Lipofectamine in accordance with the manufacturer's protocol (Invitrogen). Cells were maintained at 37degreesC and harvested at two time points after transfection (48 and 72 hours). Cells were lysed in RIPA buffer, and total protein concentration was estimated by Lowry's method. Equal amounts of protein were used for the western blot analyses. GATA3 and MUC1 immunodetection were assessed with HG3-31 and CT2 (epitope corresponding to the carboxy terminus of MUC1) monoclonal antibodies, respectively. Primary antibodies were detected with biotin-conjugated goat anti-mouse IgG (for HG3-31) or biotin-SP-conjugated goat anti-Armenian hamster IgG (for CT2) (Jackson ImmunoResearch), followed by incubation with streptavidin-conjugated HRP and using DAB as a substrate. SDS-PAGE with silver staining was employed for the detection of total protein loaded.
###end p 35
###begin p 36
###xml 76 82 76 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA3 </italic>
###xml 229 235 228 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA3 </italic>
###xml 665 670 664 669 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 805 807 804 806 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 813 815 812 814 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 422 426 <span type="species:ncbi:9925">goat</span>
###xml 432 437 <span type="species:ncbi:10090">mouse</span>
In addition, we analyzed the expression of MUC1 protein and its response to GATA3 anti-sense by an ELISA assay with MCF7 cell culture. In brief, MCF7 cells were cultured on a 96-well microtitre plate and treated with 0.05 mug of GATA3 anti-sense (48 hours), and then blocked with 1% BSA. MUC1 immunodetection was performed with HMFG1 monoclonal antibody. The bound primary antibody was detected with peroxidase-conjugated goat anti-mouse IgG. Color was developed with ABTS (2,2'-Azinobis (3-ethylbenzthiazoline-6-sulfonic acid)) substrate solution and absorbance was measured at 405 nm with a microplate reader (SLT Spectra, SLT Labinstruments, Salzburg, Austria). MUC1 expression was expressed as mean optical density with a 95% confidence interval. Statistically significant difference was estimated by t test (p < 0.05).
###end p 36
###begin title 37
Results
###end title 37
###begin title 38
GATA transcription factors family members expressed in breast epithelial cells
###end title 38
###begin p 39
###xml 25 30 25 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA </italic>
###xml 45 51 45 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA3 </italic>
###xml 92 97 92 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA </italic>
###xml 150 156 150 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA3 </italic>
###xml 287 292 287 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA </italic>
###xml 307 312 307 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA1</italic>
###xml 314 319 314 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA2</italic>
###xml 321 326 321 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA4</italic>
###xml 328 333 328 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA5</italic>
###xml 339 345 339 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA6 </italic>
###xml 428 429 428 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 519 525 519 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA3 </italic>
###xml 591 596 591 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA </italic>
###xml 678 684 678 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA3 </italic>
###xml 766 771 766 771 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 803 809 799 805 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA3 </italic>
###xml 815 817 811 813 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r </italic>
###xml 826 828 822 824 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 847 852 843 848 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 856 861 852 857 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 862 864 858 860 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r </italic>
###xml 872 874 868 870 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 896 902 892 898 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA3 </italic>
###xml 906 911 902 907 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 912 914 908 910 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r </italic>
###xml 922 924 918 920 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 941 942 937 938 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
Interestingly, among the GATA family members GATA3 was by far the most frequently expressed GATA transcription factor in breast cancer. Specifically, GATA3 was detected as being expressed in 90% of the breast cancer cases (42 out of 47) according to SAGE database analyses. In contrast, GATA family members GATA1, GATA2, GATA4, GATA5, and GATA6 were detected as expressed in only 13% (6 out of 47) of the SAGE libraries (Figure 1). Similarly, expressed sequence tag database and DNA microarray analyses showed that the GATA3 gene is expressed mainly in breast carcinomas compared with other GATA genes (Additional file 1). The MCF7 breast cancer cell line displayed the highest GATA3 expression level observed. We detected a significant positive correlation between ESR1 (the gene encoding ERalpha) and GATA3 tags (r = 0.702; p = 0.0001), between ESR1 and MUC1 (r = 0.46; p = 0.001), and between GATA3 and MUC1 (r = 0.45; p = 0.002) (Figure 1).
###end p 39
###begin title 40
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA3 </italic>
###xml 10 15 10 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
GATA3 and MUC1 real-time RT-PCR analysis in breast carcinomas
###end title 40
###begin p 41
###xml 32 38 32 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA3 </italic>
###xml 42 47 42 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 286 288 286 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r </italic>
###xml 295 297 295 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 315 317 315 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2a</xref>
###xml 352 358 352 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA3 </italic>
###xml 362 367 362 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 428 430 424 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r </italic>
###xml 439 441 435 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 450 452 446 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r </italic>
###xml 461 463 457 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 494 498 490 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2b,c</xref>
To validate the relationship of GATA3 and MUC1 in breast cancer epithelial cell further, we performed an mRNA expression analysis of 36 primary breast carcinomas by means of real-time RT-PCR. These data showed a significant positive correlation between the mRNA levels of both markers (r = 0.6; p < 0.0001) (Figure 2a). Furthermore, mRNA expression of GATA3 and MUC1 correlated positively with breast carcinomas ERalpha status (r = 0.492, p = 0.004; r = 0.608, p = 0.001, respectively) (Figure 2b,c).
###end p 41
###begin title 42
GATA3 and MUC1 tissue-microarray analysis
###end title 42
###begin p 43
###xml 41 43 41 43 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
###xml 131 137 131 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA3 </italic>
###xml 169 171 167 169 <sub xmlns:xlink="http://www.w3.org/1999/xlink">b </sub>
###xml 179 181 177 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 198 202 196 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a,b</xref>
###xml 360 362 356 358 <sub xmlns:xlink="http://www.w3.org/1999/xlink">b </sub>
###xml 370 372 366 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 395 400 391 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 483 485 477 479 <sub xmlns:xlink="http://www.w3.org/1999/xlink">b </sub>
###xml 493 495 487 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 558 564 552 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA3 </italic>
###xml 668 670 660 662 <sub xmlns:xlink="http://www.w3.org/1999/xlink">b </sub>
###xml 679 681 671 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 706 708 698 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 734 738 726 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a,c</xref>
###xml 921 923 913 915 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
PCA of 263 breast tissue samples (Figure 3a; Additional file 2) identified statistically significant positive correlations between GATA3 expression and ER/PR status (taub = 0.53; p = 0.001) (Figure 3a,b). It is interesting to note that GATA3 and MUC1 protein expression are positively correlated among normal breast samples as well as in breast carcinomas (taub = 0.44; p = 0.01). Additionally, MUC1 expression was correlated with lymph node-positive status in breast carcinomas (taub = 0.46; p = 0.006). We detected a strong correlation between the lack of GATA3 expression and higher histological tumor grade (poorly differentiated) demonstrated by multivariate (taub = -0.49; p = 0.002) and univariate (p = 0.004) analyses (Figure 3a,c). Whereas 54.3% (19 out of 35) of IDC grade I and 45% (40 out of 89) of IDC grade II tumors were GATA3-positive, only 27% (18 out of 67) of IDC grade III tumors were GATA3-positive (p = 0.013).
###end p 43
###begin p 44
###xml 91 97 91 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA3 </italic>
###xml 101 106 101 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 167 169 167 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 197 199 197 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 219 221 219 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
Overall, these studies showed a consistently statistically significant correlation between GATA3 and MUC1 expression at the mRNA and protein levels by SAGE profiling (p = 0.002), real-time RT-PCR (p < 0.0001), and TMA (p = 0.01) in breast carcinomas.
###end p 44
###begin title 45
###xml 23 26 23 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
###xml 43 48 43 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
Identification of GATA cis-elements within MUC1 promoter
###end title 45
###begin p 46
###xml 16 21 16 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 251 252 251 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 423 430 423 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 609 616 609 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 975 980 975 980 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
Analysis of the MUC1 promoter sequence indicated the presence of six putative GATA binding sites at -446/-451 (GATA1), -1444/-1449 (GATA-like), -1572/-1577 (GATA-like), -2398/-2393 (GATA3), -2475/-2470 (GATA-like), and -2602/-2607 (GATA-like) (Figure 4). These sites encode the conserved consensus sequence required for the binding of GATA factors. To determine whether GATA3 is capable of binding the -2398/-2393 sequence in vivo, we performed a chromatin immunoprecipitation (ChIP) assay with nuclear extracts obtained from the MCF7 breast cancer cell line. In brief, protein-DNA complexes were crosslinked in vivo, sonicated and then immunoprecipitated with anti-GATA3 monoclonal antibodies. DNA samples were obtained from three fractions: input, non-specific eluted, and immunoprecipitated. These DNA samples were subjected to PCR with two sets of primers that flanked the predicted GATA3-binding site (-2398/-2393) and the putative GATA1-binding site (-446/-451) in the MUC1 promoter region.
###end p 46
###begin p 47
###xml 74 83 74 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DQA1 </italic>
###xml 332 334 332 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5a</xref>
###xml 460 462 460 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5a</xref>
###xml 546 551 546 551 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
In addition, we employed a set of primers spanning the second exon of the HLA-DQA1 gene (242 bp), used as negative control because there are no GATA-binding motifs in its sequence. The amplified product corresponding to the GATA1-binding site (186 bp) was detected from input DNA and non-specific GATA3-eluted DNA fractions (Figure 5a). However, this GATA1-related amplified product was not detected from the anti-GATA3-immunoprecipitated DNA fraction (Figure 5a), indicating that the GATA3 protein does not recognize the -446/-451 site from the MUC1 promoter region.
###end p 47
###begin p 48
###xml 40 48 40 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DQA1</italic>
###xml 144 146 144 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5b</xref>
###xml 315 317 315 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5c</xref>
###xml 432 434 432 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5e</xref>
###xml 555 561 555 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA3 </italic>
###xml 718 723 718 723 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 761 762 761 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 853 858 853 858 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 975 976 975 976 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 1084 1086 1084 1086 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6b</xref>
Identical results were obtained for the HLA-DQA1-amplified products (negative control), demonstrating the specificity of the ChIP assay (Figure 5b). In contrast, the amplified product spanning the GATA3-binding site (292 bp in size) was detected in the input and anti-GATA3-immunoprecipitated DNA fractions (Figure 5c). These amplified products were detected only in the second immunoprecipitated DNA fraction (reChIP assay; Figure 5e). Furthermore, we employed an EMSA approach to validate the ChIP findings. Nuclear extract retarded the mobility of the GATA3 sequence-specific probe (positive control) and the probe encoding the putative GATA3-binding site (5'-ggcggatctttgatagactggagtgtc-3') found in the wild-type MUC1 promoter region (-2398/-2393) (Figure 6). In contrast, electromobility was not affected when a point mutant of the aforementioned MUC1 probe (T/CTTA/G instead of the wild-type T/GATA/G) was employed, indicating that no protein binding occurred (Figure 6). The presence of GATA3 in the retarded probe-protein complex was confirmed by supershift analysis (Figure 6b). The addition of anti-GATA3 antibody to the binding reaction showed a further decrease in the mobility of the probe-protein complex. Addition of the control antibody (anti-ERbeta) had no effect.
###end p 48
###begin p 49
###xml 170 175 170 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 215 223 215 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 227 236 227 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
Overall, these data indicate that endogenous GATA3 protein molecules from the MCF7 breast cancer cell line were able to associate with the putative GATA3-binding site of MUC1 promoter sequence, as demonstrated with in vivo and in vitro assays.
###end p 49
###begin title 50
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA3 </italic>
GATA3 anti-sense assay
###end title 50
###begin p 51
###xml 38 43 38 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 62 68 62 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA3 </italic>
###xml 234 240 234 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA3 </italic>
###xml 404 410 403 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA3 </italic>
###xml 551 553 550 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7a</xref>
###xml 603 608 602 607 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 627 628 626 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7</xref>
###xml 877 879 876 878 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7b</xref>
To investigate the effect of GATA3 on MUC1 gene expression, a GATA3 knock-down assay was performed with specific anti-sense oligonucleotides in MCF7 and T47D breast cancer cell lines. Cells were treated with optimal concentrations of GATA3 anti-sense oligonucleotides (3 mug/ml) and examined 48 and 72 hours after transfection. Immunoblotting analyses of the cells treated with MCF7 and T47D showed that GATA3 translation was blocked by the anti-sense oligonucleotide at both time points analyzed (namely at 48 and 72 hours after transfection; Figure 7a). Treated cells showed a significant decrease in MUC1 expression (Figure 7). Total protein staining showed that these results were not due to differences in protein loading. The same result was obtained in a separate experiment with a MCF7-cell ELISA assay with a different monoclonal antibody (HMFG1) against MUC1 (Figure 7b).
###end p 51
###begin title 52
Discussion
###end title 52
###begin p 53
###xml 49 55 49 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA3 </italic>
###xml 127 128 123 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 129 130 125 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 241 245 237 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1</italic>
###xml 247 252 243 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA3</italic>
###xml 258 263 254 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 328 329 324 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 332 333 328 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 669 675 665 671 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA3 </italic>
###xml 679 684 675 680 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 727 729 723 725 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 745 747 741 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2a</xref>
###xml 752 754 748 750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
###xml 920 922 916 918 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
Transcriptome profile analyses demonstrated that GATA3 expression is strongly correlated with ERalpha status in breast cancer [3-9]. Recently we performed a cross-platform comparison between SAGE and DNA microarray profiles showing that the ESR1, GATA3, and MUC1 genes are very tightly co-expressed in breast carcinomas (Figure 1) [3]. To validate the relationship of GATA3 and MUC1 in breast tissues further, we performed mRNA expression analyses of 36 invasive breast carcinomas by real-time RT-PCR, and protein expression analysis in 263 breast tissue samples by means of immunohistochemistry on TMAs. Both analyses showed a statistical positive correlation between GATA3 and MUC1 expression at the mRNA and protein levels (p < 0.01; Figures 2a and 3a). Interestingly, we also detected a positive correlation between GATA3 and MUC1 protein expression when both markers were evaluated in normal breast tissue as well (p = 0.001).
###end p 53
###begin p 54
###xml 192 196 192 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC2</italic>
###xml 198 202 198 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC3</italic>
###xml 208 213 208 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC4 </italic>
###xml 214 216 214 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 217 219 217 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 317 322 317 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
Two recent studies from gastrointestinal epithelial cells indicated that GATA family members (GATA4 and GATA5) may have pivotal roles in the transcriptional upregulation of three mucin genes: MUC2, MUC3, and MUC4 [14,15]. These data led us to infer that GATA3 might have a role in the transcriptional upregulation of MUC1 in breast epithelium.
###end p 54
###begin p 55
###xml 81 86 81 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 163 171 163 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 175 183 175 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 346 351 346 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 368 369 368 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 425 426 425 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 543 548 543 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 681 687 681 687 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA3 </italic>
###xml 797 798 797 798 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7</xref>
###xml 866 871 866 871 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
To determine whether GATA3 protein was actively bound to the predicted consensus MUC1 promoter sequence (at -2398/-2393 from the transcriptional start site (TSS)) in vivo and in vitro, we performed ChIP and gel shift analyses in breast cancer cells. The ChIP assay in MCF7 demonstrated the existence of a functional GATA3 binding site within the MUC1 promoter (Figure 5). The EMSA studies further validated ChIP data (Figure 6). Having found that GATA3 transcription factor efficiently recognizes a sequence motif in the distal portion of the MUC1 promoter, we proceeded to analyze the effects of GATA3 suppression on MUC1 protein expression in transiently transfected MCF7 cells. GATA3 knockdown assays led to a significant decrease in MUC1 protein expression in MCF7 breast cancer cells (Figure 7), strongly suggesting an involvement of GATA3 in the modulation of MUC1 expression.
###end p 55
###begin p 56
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 117 119 117 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 120 122 120 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 413 418 413 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 450 452 450 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 683 685 683 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 686 688 686 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 731 737 731 737 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA3 </italic>
###xml 787 792 787 792 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 851 856 851 856 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 885 891 885 891 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA3 </italic>
###xml 895 900 895 900 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 1131 1137 1131 1137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA3 </italic>
###xml 1141 1146 1141 1146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 1201 1206 1201 1206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
The MUC1 promoter sequence has been analyzed previously for its ability to direct the expression of a reporter gene [19-21]. The construct (including 2.9 kb of MUC1 5'-flanking region) showed high expression levels in ZR75 cells but surprisingly low levels in MCF7 and T47D cell lines. This study showed that tissue-specific expression of a reporter gene could be obtained with only 743 bp of 5' sequences of the MUC1 gene, using the ZR75 cell line [19]. However, the binding of GATA3 to the promoter regions of target genes generate an open chromatin configuration that increases the accessibility to other main transcriptional regulators (perhaps STAT) in the vicinity of the TSS [30,31]. These data, together with the fact that GATA3 knock-down expression did not immediately abolish MUC1 expression, suggest that GATA3 is partly required to drive MUC1 expression. The finding that GATA3 and MUC1 expression were correlated in SAGE, real-time RT-PCR and TMA immunohistochemistry analyses shows statistical significance. It is also apparently a set of breast carcinomas in which there was no direct correlation between levels of GATA3 and MUC1 expression. This suggests that GATA3 may contribute to MUC1 upregulation in a subset of breast cancer cells (namely ERalpha-positive breast carcinoma).
###end p 56
###begin p 57
###xml 54 59 54 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 83 86 83 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
###xml 157 162 157 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 319 324 315 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 364 369 360 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 395 398 391 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
###xml 493 495 489 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 624 626 620 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 787 789 783 785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 924 929 920 925 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 969 971 965 967 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
The role of GATA3 as a transcriptional upregulator of MUC1 could be directly via a cis-acting interaction and/or indirectly via cross-talk between GATA3 and MUC1 co-activators such as ERalpha/SP1, STAT or FOG (friend-of-GATA cofactors). The transcriptional regulatory event, operating after the binding of GATA3 to the MUC1 promoter, remains to be determined. The MUC1 promoter contains several cis-elements specific for transcription in lymphoid cells such as STAT, MZF1, XBP1, MYB and GATA [21]. The involvement of GATA and STAT proteins in cytokine signaling is well documented in the hematopoietic and lymphoid systems [30]. Interestingly, a GATA-STAT synergy has been recently suggested as a general event that could account for cell-specific effects of transcriptional regulation [31]. The presence of these elements, which can upmodulate gene expression in lymphoid cells, are in accord with the observation that the MUC1 gene is expressed in activated T cells [32].
###end p 57
###begin p 58
###xml 120 125 120 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 156 158 156 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 182 184 182 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 294 299 294 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 449 451 445 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 544 549 540 545 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 597 599 593 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 600 602 596 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 721 723 713 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 724 726 716 718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 867 869 855 857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 114 119 <span type="species:ncbi:9606">human</span>
###xml 264 268 <span type="species:ncbi:10090">mice</span>
Alternatively, several putative estrogen and progesterone response elements (ERE/PRE) have been identified in the human MUC1 promoter by sequence analysis [33]. Zhou and colleagues [34] demonstrated that ER does not directly regulate the Muc1 promoter sequence in mice. It is possible that the MUC1 gene is transcriptionally regulated by non-ERE-mediated mechanisms, for example those involving ERalpha binding to a co-activator such as AP1 or SP1 [35]. It is interesting to note that two SP1-binding sites have been characterized as important MUC1 transcriptional activators in epithelial cells [19,20]. Moreover, there are studies demonstrating protein-protein interaction between ERalpha and GATA1 in erythroid cells [36,37]. ERalpha binds to the GATA1 protein at two sites, one of which is a zinc-finger domain that is highly conserved among GATA family members [36].
###end p 58
###begin p 59
###xml 40 44 40 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1</italic>
###xml 46 51 46 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA3</italic>
###xml 57 62 57 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 206 211 202 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
Therefore, a possible way of explaining ESR1, GATA3, and MUC1 co-expression could very probably involve the formation of a complex between the ERalpha and GATA3 proteins that results in the upmodulation of MUC1 gene expression.
###end p 59
###begin p 60
###xml 42 48 42 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA3 </italic>
###xml 83 93 83 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in silico </italic>
###xml 127 129 127 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 527 529 527 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 572 574 572 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 596 602 596 602 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA3 </italic>
It has been shown that high expression of GATA3 correlates with low tumor grade by in silico analysis of cDNA microarray data [12]. As is known, tumor grade is a good measure of breast cancer progression and differentiation status. In this study we have demonstrated a strong correlation between loss of GATA3 protein expression and more advanced stages of breast cancer progression; that is, high-grade less differentiated breast carcinomas expressed lower levels of GATA3 protein on the basis of immunohistochemical studies (p = 0.004). Similarly, Mehra and colleagues [38] showed that loss of GATA3 expression is associated with higher histological grade.
###end p 60
###begin p 61
###xml 355 357 355 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 358 360 358 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 526 528 523 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 674 679 671 676 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
Our data agree with previously reported studies showing the role of GATA family members in the development and maintenance of a more differentiated state. Interestingly, there is emerging evidence that membrane-associated mucins (MUC1 and MUC4) contribute to the regulation of differentiation, morphogenesis, and proliferation of breast epithelial cells [17,39]. Recent data show that a fragment of the MUC1 cytoplasmic tail can be translocated to the nucleus, driving the transcriptional co-activator status of beta-catenin [40]. This finding sustains the possibility that GATA3 might influence cell differentiation possibly through processes involving the upregulation of MUC1 gene expression.
###end p 61
###begin title 62
Conclusion
###end title 62
###begin p 63
###xml 88 93 88 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
Our findings suggest that GATA3 could contribute to the transcriptional upregulation of MUC1 gene expression in some breast carcinomas.
###end p 63
###begin title 64
Abbreviations
###end title 64
###begin p 65
###xml 213 218 213 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 297 308 <span type="species:ncbi:3704">horseradish</span>
bp = base pairs; ChIP = chromatin immunoprecipitation; DAB = diaminobenzidine; DTT = dithiothreitol; ELISA = enzyme-linked immunosorbent assay; EMSA = electrophoretic mobility-shift assay; ER = estrogen receptor; ESR1 = gene encoding estrogen receptor alpha; GATA3 = GATA-binding protein 3; HRP = horseradish peroxidase; IDC = invasive ductal carcinoma; MUC1 = mucin 1; PR = progesterone receptor; RT-PCR = reverse-transcriptase-mediated polymerase chain reaction; SAGE = serial analysis of gene expression; TMA = tissue microarray.
###end p 65
###begin title 66
Competing interests
###end title 66
###begin p 67
The authors declare that they have no competing interests.
###end p 67
###begin title 68
Authors' contributions
###end title 68
###begin p 69
MCA conceived the study idea and carried out the experimental analyses and the biostatistical/bioinformatics analysis and took part in writing the manuscript. MIN coordinated and performed pathological and tissue microarray immunohistochemical studies. AGC and MVC participated in cell culture/immunohistochemistry studies and provided practical feedback on aspects of the manuscript. CMA and AS are principal investigators and were involved in the conceptualization, design and writing of the manuscript. All authors read and approved the final manuscript.
###end p 69
###begin title 70
Supplementary Material
###end title 70
###begin title 71
Additional file 1
###end title 71
###begin p 72
A PDF file showing a cross-platform comparison of GATA family members expressed in breast carcinomas using SAGE, expressed sequence tag and DNA microarray databases.
###end p 72
###begin p 73
Click here for file
###end p 73
###begin title 74
Additional file 2
###end title 74
###begin p 75
A PDF file showing a principal components analysis of tissue microarray data.
###end p 75
###begin p 76
Click here for file
###end p 76
###begin title 77
Acknowledgements
###end title 77
###begin p 78
The authors gratefully acknowledge Dr Andres JP Klein-Szanto (Fox Chase Cancer Center), who kindly provided breast cancer TMAs; Nancy W Abbey for her outstanding technical assistance, Dr Marina Isla-Larrain for the development of the ELISA assay, and Dr J Carri for help with the photography. This work was supported by NIH-NCI Grant 1U19 CA84978-1A1 (C.M. Aldaz) and center grant ES-07784, FONCYT (PICT Ndegrees05-06544, BID 1201/OC/AR 1253), CONICET, CICPBA and University of La Plata (Argentina).
###end p 78
###begin article-title 79
DNA-binding specificity of GATA family transcription factors
###end article-title 79
###begin article-title 80
The GATA family (vertebrates and invertebrates)
###end article-title 80
###begin article-title 81
Gene expression signature of estrogen receptor alpha status in breast cancer
###end article-title 81
###begin article-title 82
GATA-3 is expressed in association with estrogen receptor in breast cancer
###end article-title 82
###begin article-title 83
###xml 23 28 <span type="species:ncbi:9606">human</span>
Molecular portraits of human breast tumors
###end article-title 83
###begin article-title 84
Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns
###end article-title 84
###begin article-title 85
###xml 34 39 <span type="species:ncbi:9606">human</span>
Predicting the clinical status of human breast cancer by using gene expression profiles
###end article-title 85
###begin article-title 86
Gene expression profiling predicts clinical outcome of breast cancer
###end article-title 86
###begin article-title 87
Breast cancer classification and prognosis based on gene expression profiles from a population-base study
###end article-title 87
###begin article-title 88
GATA-3 expression as a predictor of hormone response in breast cancer
###end article-title 88
###begin article-title 89
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
###end article-title 89
###begin article-title 90
###xml 21 26 <span type="species:ncbi:9606">human</span>
Mutation of GATA3 in human breast tumors
###end article-title 90
###begin article-title 91
Transcription factor GATA-6 activates expression of gastroprotective trefoil genes TFF1 and TFF2
###end article-title 91
###begin article-title 92
Transcription factor GATA-5 selectively up-regulates mucin gene expression
###end article-title 92
###begin article-title 93
###xml 4 10 <span type="species:ncbi:10090">murine</span>
The murine Muc2 mucin gene is transcriptionally regulated by the zinc-finger GATA-4 transcription factor in intestinal cells
###end article-title 93
###begin article-title 94
MUC1, the renaissance molecule
###end article-title 94
###begin article-title 95
Mucins in cancer: protection and control of the cell surface
###end article-title 95
###begin article-title 96
A STAT-responsive element in the promoter of Episialin/MUC1 gene is involved in its overexpression in carcinoma cells
###end article-title 96
###begin article-title 97
Analysis of the tissue-specific promoter of the MUC1 gene
###end article-title 97
###begin article-title 98
Two GC boxes (Sp1 sites) are involved in regulation of activity of the epithelium-specific MUC1 promoter
###end article-title 98
###begin article-title 99
Analysis of the promoter of the MUC1 gene overexpressed in breast cancer
###end article-title 99
###begin article-title 100
###xml 96 101 <span type="species:ncbi:9606">human</span>
MZF-1 and DbpA interact with DNase I hypersensitive sites that correlate with expression of the human MUC1 mucin gene
###end article-title 100
###begin article-title 101
Cancer Genome Anatomy Project - SAGE Genie
###end article-title 101
###begin article-title 102
Science Park Research Division - Sage Library Tool
###end article-title 102
###begin article-title 103
Oncomine - Cancer Profiling Database
###end article-title 103
###begin article-title 104
Frequent loss of WWOX expression in breast cancer: correlation with estrogen receptor status
###end article-title 104
###begin article-title 105
HLA-DQA1 allele typing by nonisotopic PCR-LIS-SSCP
###end article-title 105
###begin article-title 106
###xml 150 155 <span type="species:ncbi:9606">human</span>
Electrophoretic mobility shift assay for the detection of specific DNA-protein complex in nuclear extracts from the cultured cells and frozen autopsy human brain tissue
###end article-title 106
###begin article-title 107
Function of GATA transcription factors in induction of endothelial vascular cell adhesion molecule-1 by tumor necrosis factor-alpha
###end article-title 107
###begin article-title 108
Conditional deletion of Gata3 shows its essential function in Th1-Th2 responses
###end article-title 108
###begin article-title 109
Convergence of protein kinase C and JAK-STAT signaling on transcription factor GATA-4
###end article-title 109
###begin article-title 110
###xml 38 43 <span type="species:ncbi:9606">human</span>
Expression of MUC1 mucin on activated human T cells: implications for a role of MUC1 in normal immune regulation
###end article-title 110
###begin article-title 111
MUC1: a multifunctional cell surface component of reproductive tissue epithelia
###end article-title 111
###begin article-title 112
###xml 49 55 <span type="species:ncbi:10090">murine</span>
Estrogen receptor does not directly regulate the murine Muc-1 promoter
###end article-title 112
###begin article-title 113
Anatomy of the estrogen response element
###end article-title 113
###begin article-title 114
Ligand-dependent repression of the erythroid transcription factor GATA-1 by the estrogen receptor
###end article-title 114
###begin article-title 115
Estrogen-induced apoptosis by inhibition of the erythroid transcription factor GATA-1
###end article-title 115
###begin article-title 116
Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis
###end article-title 116
###begin article-title 117
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human MUC1 mucin: a potent glandular morphogen
###end article-title 117
###begin article-title 118
Nuclear association of the cytoplasmic tail of muc1 and beta-catenin
###end article-title 118
###begin title 119
Figures and Tables
###end title 119
###begin p 120
###xml 48 53 48 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA </italic>
###xml 69 74 69 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1 </italic>
###xml 78 83 78 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
Digital northern analysis based on SAGE data of GATA family members, ESR1 and MUC1 genes in 47 breast SAGE libraries. The color scale at the bottom represents expression level based on numbers of transcripts (tags) per library. SAGE, serial analysis of gene expression.
###end p 120
###begin p 121
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA3 </italic>
###xml 10 15 10 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 75 79 75 79 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 109 115 109 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA3 </italic>
###xml 119 124 119 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 217 219 217 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r </italic>
###xml 226 228 226 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 239 245 239 245 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b,c) </bold>
###xml 245 251 245 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA3 </italic>
###xml 252 254 252 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 271 276 271 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 277 279 277 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 503 505 497 499 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
GATA3 and MUC1 real-time RT-PCR analysis in 36 invasive breast carcinomas. (a) Linear regression analysis of GATA3 and MUC1 mRNA expression levels in invasive ductal carcinoma (IDC) with 95% mean prediction interval (r = 0.6; p < 0.0001). (b,c) GATA3 (p = 0.008) (b) and MUC1 (p = 0.009) (c) mRNA expression of IDC in association with ERalpha status. Results are real-time RT-PCR values of the assayed gene relative to 18S rRNA used as normalizing control and are shown as means +/- 2 SEM based on a log2 transformation.
###end p 121
###begin p 122
###xml 75 79 75 79 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 205 207 205 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 231 233 231 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 271 273 271 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 295 297 295 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 367 369 367 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 402 404 402 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 414 420 414 420 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b,c) </bold>
###xml 530 532 530 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 644 646 644 646 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
Tissue microarray analysis of 263 breast normal and cancer tissue samples. (a) Component plot in rotated space showing factors positively correlated, namely estrogen receptor/progesterone receptor (ER/PR; p = 0.0001), ER-PR/GATA3 (p = 0.001), and MUC1/lymph node status (p = 0.006), GATA3/MUC1 (p = 0.01); and factors negatively correlated, namely ER-PR/tumor grade (p = 0.0001) and GATA3/tumor grade (p = 0.002). (b,c) Univariate analysis showing highly statistical association between GATA3 immunostaining and ER and PR status (p = 0.0001) (b) and statistical decrease trend in GATA3 immunostaining and the tumor grade of invasive component (p = 0.004) (c). Results are based on the brown intensity of immunostaining as described in the Materials and methods section, and are shown as means +/- 2 SEM.
###end p 122
###begin p 123
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 24 28 24 28 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 33 36 33 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
###xml 64 69 64 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 86 90 86 90 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
MUC1 promoter sequence. (a) GATA cis-elements map identified in MUC1 promoter region. (b) DNA sequence showing the TATA box (white box), the transcriptional start site +1 (TSS arrow) and the open reading frame (ORF arrow). Gray boxes indicate putative binding sites for GATA transcription factors showing the following: a GATA1 sequence (-448), a GATA3 sequence (-2395) and four GATA-like sequences (-1446, -1574, -2472, and -2604). Known regulatory elements are underlined (Sp1, STAT1/3, E-MUC1).
###end p 123
###begin p 124
###xml 111 119 111 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 531 537 531 537 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a&#8211;c) </bold>
###xml 620 625 620 625 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 842 847 842 847 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 887 893 887 893 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(d&#8211;e) </bold>
###xml 980 984 980 984 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(f) </bold>
###xml 1114 1120 1114 1120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA3 </italic>
###xml 247 252 <span type="species:ncbi:10090">mouse</span>
Chromatin immunoprecipitation assay of GATA3 in MCF7 breast cancer cells. Chromatin complexes were crosslinked in vivo with formaldehyde (see the Materials and methods section). The GATA3-associated DNA fragments were immunoprecipitated (IP) with mouse monoclonal antibody against GATA3 (HG3-31). DNA samples were isolated before IP (lane labeled 'input'), after elution the unbound proteins from the Protein A-Sepharose batch (lane labeled 'eluted') and after specific IP (lane labeled 'ChIP', for chromatin immunoprecipitation). (a-c) PCR was performed with (a) flanking primers amplifying a GATA1 binding site on the MUC1 promoter (186 bp; see Figure 2), (b) flanking primers for amplification of exonic sequences of the HLA-DQA1 gene (242 bp; negative control), and (c) flanking primers for amplification of the GATA3-binding site on the MUC1 promoter (292 bp) as shown in Figure 2. (d-e) Second ChIP (reChIP) assay using the first eluted DNA-protein complex as input sample. (f) Western blot analysis of GATA3 protein expression: a sample of MCF7 protein extract was run on a 10% SDS-PAGE gel and assayed for GATA3 expression with the monoclonal antibody used in ChIP assays (HG3-31). The expected wild-type band of 48 kDa was immunodetected. Lane WM shows an SDS-7B prestained SDS-molecular mass standard (Sigma-Aldrich).
###end p 124
###begin p 125
###xml 79 83 79 83 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 414 418 414 418 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
Electrophoretic mobility-shift assay employing cell nuclear extract from MCF7. (a) Gel shift analyses were performed with double-stranded oligonucleotides (27 bp) as indicated: positive control probe containing the GATA3-binding element (GATA3-wt), a mimetic wild-type MUC1 probe containing the predictive GATA3-binding site (MUC1-wt), and a probe sequence with predictive GATA3-binding site mutations (MUC1-mut). (b) The presence of GATA3 was confirmed by supershift assay. Nuclear extract prepared from MCF7 cells was preincubated with GATA3 antibody, and then incubated with the mimetic wild-type MUC1 probe containing the GATA3-binding site (MUC1-wt). Arrows to the right indicate the position of the free probe (FP), the probe-nuclear-protein complex (Complex), and the specifically retarded protein-GATA3-antibody-probe complex (Supershift).
###end p 125
###begin p 126
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA3 </italic>
###xml 69 73 69 73 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 151 157 151 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA3 </italic>
###xml 313 317 313 317 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 345 351 345 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA3 </italic>
###xml 505 509 505 509 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 580 586 580 586 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATA3 </italic>
###xml 669 674 669 674 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1 </italic>
###xml 722 724 722 724 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
GATA3 knock-down analysis in MCF7 and T47D breast cancer cell lines. (a) Western blot analysis of GATA3 and MUC1 proteins in non-treated (control) and GATA3 anti-sense treated cells (48 and 72 hours) in both breast cancer cell lines. SDS-PAGE silver protein staining showed equal amounts of total protein loaded. (b) MCF7 immunocytochemistry of GATA3 anti-sense transfected cells showing no immunoreactivity to the anti-GATA3 antibody, and matching control cells show GATA3-positive nuclear localization. (c) Quantification of MUC1 protein expression by MCF7 culture ELISA assay. GATA3 anti-sense treated cells (48 hours) showed a statistically significant decrease in MUC1 expression compared with matched control cells (p = 0.001). Each experiment was performed in triplicate.
###end p 126

